We were very interested to read the article entitled 'The clinical utility of early use of tolvaptan in very elderly patients with acute decompensated heart failure' by Niikura et al. (1) recently published in the Anatol J Cardiol 2017; 18: 206-12 and the editorial comment entitled 'Tolvaptan in the very elderly with acute decompensated heart failure-a therapeutic option worth of consideration' by Ndrepepa (2) in the same issue, which evaluated the safety and efficacy of tolvaptan, a selective vasopressin V2 receptor antagonist, in very elderly patients.
